Foralumab TZLS-401 100 µg
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Active Secondary Progressive Multiple Sclerosis
Conditions
Non-Active Secondary Progressive Multiple Sclerosis
Trial Timeline
Mar 4, 2025 → Aug 30, 2026
NCT ID
NCT06890923About Foralumab TZLS-401 100 µg
Foralumab TZLS-401 100 µg is a phase 2 stage product being developed by Tiziana Life Sciences for Non-Active Secondary Progressive Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06890923. Target conditions include Non-Active Secondary Progressive Multiple Sclerosis.
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06890923 | Phase 2 | Recruiting |
Competing Products
1 competing product in Non-Active Secondary Progressive Multiple Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Foralumab TZLS-401 50 µg | Tiziana Life Sciences | Pre-clinical | 20 |